Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4268-4276

  Moretti, Silvia ^a   Bozza, Silvia ^a   D'Angelo, Carmen ^a   Casagrande, Andrea ^a   Della Fazia, Maria Agnese ^a   Pitzurra, Lucia ^a   Romani, Luigina ^a   Aversa, Franco ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; DECTIN 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFECT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INVASIVE ASPERGILLOSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; ECHINOCANDINS; FEMALE; HUMANS; LECTINS, C-TYPE; LUNG; LUNG DISEASES, FUNGAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; RECEPTORS, IMMUNOLOGIC; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 9;

EID: 84864386822     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05198-11     Document Type: Article

References (43)

1. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. 2007. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob. Agents Chemother. 51:881-887. (Pubitemid 46355271)
2. Barchiesi F, et al. 2005. Efficacy of caspofungin against Aspergillus terreus. Antimicrob. Agents Chemother. 49:5133-5135. (Pubitemid 41778933)
3. Bellocchio S, et al. 2005. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother. 55:214-222. (Pubitemid 40331148)
4. Bellocchio S, et al. 2004. TLRs govern neutrophil activity in aspergillosis. J. Immunol. 173:7406-7415. (Pubitemid 39628180)
5. Ben-Ami R, Lewis RE, Kontoyiannis DP. 2008. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin. Infect. Dis. 47:226-235. (Pubitemid 351952889)
6. Bizerra FC, et al. 2011. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob. Agents Chemother. 55:302-310.
7. Bowman JC, et al. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474-3481. (Pubitemid 33107865)
8. Cacciapuoti A, et al. 2006. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob. Agents Chemother. 50:2587-2590. (Pubitemid 43993212)
9. Cagas SE, Jain MR, Li H, Perlin DS. 2011. Profiling the Aspergillus fumigatus proteome in response to caspofungin. Antimicrob. Agents Chemother. 55:146-154.
10. Carvalho A, et al. 2012. Dectin-1 isoforms contribute to distinct Th1/Th17 cell activation in mucosal candidiasis. Cell. Mol. Immunol. 9:276-286.
11. Chen SC, Slavin MA, Sorrell TC. 2011. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71:11-41.
12. Cunha C, Romani L, Carvalho A. 2010. Cracking the Toll-like receptor code in fungal infections. Expert Rev. Anti Infect. Ther. 8:1121-1137.
13. Drummond RA, Brown GD. 2011. The role of Dectin-1 in the host defence against fungal infections. Curr. Opin. Microbiol. 14:392-399.
14. Fera MT, La Camera E, De Sarro A. 2009. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev. Anti Infect. Ther. 7:981-998.
15. Fortwendel JR, et al. 2010. Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. Antimicrob. Agents Chemother. 54:1555-1563.
16. Gaziano R, et al. 2004. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob. Agents Chemother. 48:4414-4421. (Pubitemid 39434905)
17. Hohl TM, Feldmesser M, Perlin DS, Pamer EG. 2008. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J. Infect. Dis. 198:176-185. (Pubitemid 352019282)
18. Kaneko Y, Ohno H, Imamura Y, Kohno S, Miyazaki Y. 2009. The effects of an hsp90 inhibitor on the paradoxical effect. Jpn. J. Infect. Dis. 62:392-393.
19. Lamaris GA, et al. 2008. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J. Infect. Dis. 198:186-192. (Pubitemid 352019283)
20. Lass-Florl C, Perkhofer S, Mayr A. 2010. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Mycoses 53:1-11.
21. Lee KK, et al. 2011. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob. Agents Chemother. 56:208-217.
22. Lewis RE, Albert ND, Kontoyiannis DP. 2008. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 61:1140 -1144.
23. Lewis RE, Liao G, Hou J, Prince RA, Kontoyiannis DP. 2011. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. J. Antimicrob. Chemother. 66:1324 -1331.
24. Mulanovich VE, Kontoyiannis DP. 2011. Fungal pneumonia in patients with hematologic malignancies: current approach and management. Curr. Opin. Infect. Dis. 24:323-332.
25. NCCLS. 2002. Method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A2, 2nd ed, vol 22, no 16. National Committee for Clinical Laboratory Standards, Wayne, PA.
26. Pappas PG, et al. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50:1101-1111.
27. Perlin DS. 2011. Current perspectives on echinocandin class drugs. Future Microbiol. 6:441-457.
28. Plaine A, et al. 2008. Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. Fungal Genet. Biol. 45:1404-1414.
29. Ramirez-Ortiz ZG, et al. 2008. Toll-like receptor 9-dependent immune activation by unmethylated CpG motifs in Aspergillus fumigatus DNA. Infect. Immun. 76:2123-2129. (Pubitemid 351656146)
30. Rocha EM, Garcia-Effron G, Park S, Perlin DS. 2007. A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 51:4174-4176. (Pubitemid 350057823)
31. Romani L. 2011. Immunity to fungal infections. Nat. Rev. Immunol. 11:275-288.
32. Romani L, et al. 2008. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451:211-215.
33. Salvenmoser S, Seidler MJ, Dalpke A, Muller FM. 2010. Effects of caspofungin, Candida albicans and Aspergillus fumigatus on toll-like receptor 9 of GM-CSF-stimulated PMNs. FEMS Immunol. Med. Microbiol. 60:74 -77.
34. Segal BH, et al. 2008. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin. Infect. Dis. 47:674-683.
35. Sherif R, Segal BH. 2010. Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Curr. Opin. Pulm. Med. 16:242-250.
36. Simitsopoulou M, et al. 2008. Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors. Antimicrob. Agents Chemother. 52:3301-3306.
37. Sorci G, et al. 2011. The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation. PLoS Pathog. 7:e1001315. doi:10.1371/journal.ppat.1001315.
38. Steinbach WJ. 2010. Invasive aspergillosis in pediatric patients. Curr. Med. Res. Opin. 26:1779-1787.
39. Stevens DA. 2009. Frequency of paradoxical effect with caspofungin in Candida albicans. Eur. J. Clin. Microbiol. Infect. Dis. 28:717.
40. Wheeler RT, Fink GR. 2006. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2:e35. doi:10.1371/journal.ppat.0020035.
41. Wiederhold NP. 2007. Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. Curr. Opin. Infect. Dis. 20:574-578. (Pubitemid 350059516)
42. Wiederhold NP. 2009. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med. Mycol. 47(Suppl. 1):S369-S375.
43. Wiederhold NP, et al. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464 -1471.